REG - Avacta Group PLC - Appointment of Nominated Adviser & TVR

AvactaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260120:nRST5119Pa&default-theme=true

RNS Number : 5119P  Avacta Group PLC  20 January 2026

 

Appointment of Nominated Adviser

Total Voting Rights Update

 

LONDON and PHILADELPHIA - January 20, 2026 - Avacta Therapeutics (AIM: AVCT,
"the Company", "Avacta"), a clinical stage biopharmaceutical company
developing pre|CISION(®), a tumor-activated oncology delivery platform,
announces the appointment of Strand Hanson Limited as the Company's Nominated
Adviser, with immediate effect.

 

Correction to Total Voting Rights

 

The Company's issued ordinary share capital is 440,415,495 Ordinary Shares.
This figure may be used by holders of Ordinary Shares as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the share capital of the
Company under the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.

 

Additional information is disclosed below under Schedule Two, paragraph (g) of
the AIM Rules for Companies.

 

-Ends-

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                           https://avacta.com/ (https://avacta.com/)

 Christina Coughlin, Chief Executive Officer                via ICR Healthcare

 Strand Hanson Limited (Nominated Adviser)                   www.strandhanson.co.uk (http://www.strandhanson.co.uk)

 James Harris / Chris Raggett / James Dance

 Zeus (Broker)                                              www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry / Dominic King

 ICR Healthcare                                             avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 Investor Contact                                           renee@thrustsc.com (mailto:renee@thrustsc.com)

 Renee Leck

 THRUST Strategic Communications

 Media Contact                                               carly@thrustsc.com (mailto:carly@thrustsc.com)

 Carly Scaduto

 THRUST Strategic Communications

 

 

AIM Rule 17 Updates

 

In addition to the disclosures made in the announcement of Richard Hughes's
appointment to the Board on 28 May 2025, Richard Hughes was:

 

appointed a director of Trafford Finance Limited on 28 October 2009, a company
incorporated in England and Wales. The company was placed into administration
on 21 April 2010 and was subsequently dissolved on 19 September 2013, with an
estimated £5.4 million owed to creditors;

 

appointed a director of Procurasell International (Packaging) Ltd on 30
October 2007, a company incorporated in England and Wales. The company was
placed into administration on 8 January 2009 and was subsequently dissolved on
23 September 2010, with approximately £0.1 million owing to creditors; and

 

appointed a director of Holyrood Leisure Limited on 26 April 2007, a company
incorporated in England and Wales. The company was placed into administration
on 28 June 2018 and was subsequently dissolved on 25 February 2020, with
approximately £0.5 million owing to creditors.

 

About Avacta - www.avacta.com (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary payload delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent payloads in the tumor microenvironment
while sparing normal tissues.

 

Our innovative pipeline consists of pre|CISION(®) peptide drug conjugates
(PDC) or Affimer(®) drug conjugates (AffDC) that leverage the tumor-specific
release mechanism, providing unique benefits over traditional antibody drug
conjugates.

 

The pre|CISION(®) platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumors compared
with healthy tissues. The pre|CISION(®) platform harnesses this tumor
specific protease to cleave pre|CISION(®) peptide drug conjugates and
pre|CISION(®) antibody/Affimer(®) drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and reducing
systemic exposure and toxicity, allowing dosing to be optimized to deliver the
best outcomes for patients.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPFFFVLLDIALIR



            Copyright 2019 Regulatory News Service, all rights reserved